Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000653476 | SCV000775355 | uncertain significance | Pancreatic adenocarcinoma | 2022-09-01 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 542935). This variant has not been reported in the literature in individuals affected with PALLD-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.006%). This sequence change replaces leucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 433 of the PALLD protein (p.Leu433Arg). |
Ambry Genetics | RCV004025908 | SCV002749042 | uncertain significance | not specified | 2024-05-27 | criteria provided, single submitter | clinical testing | The p.L920R variant (also known as c.2759T>G), located in coding exon 15 of the PALLD gene, results from a T to G substitution at nucleotide position 2759. The leucine at codon 920 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |